Orchestra BioMed Holdings, Inc. (OBIO) is a New Hope, Pennsylvania-based biomedical innovation company developing two flagship device candidates: AVIM Therapy, a pacemaker-delivered bioelectronic treatment for uncontrolled hypertension being developed with Medtronic (MDT), and Virtue SAB, a non-coated sirolimus delivery balloon for coronary and peripheral artery disease partnered with Terumo.
In Wednesday's session, the stock rose 10.62%, trading at $7.71 against the previous close of $6.97. The direction is unambiguously higher, and the move lifts shares to their highest level in more than a year, above the $7.45 intraday peak reached earlier this week. No new press release, filing, or data readout accompanied the session, so the gain is best understood as continuation buying in the wake of a cluster of verified fundamental and analyst developments from the prior week.
The most concrete verified catalyst in the run-up to Wednesday's move was a coordinated round of price target increases following the company's research and development day. Piper Sandler reiterated a Buy rating and a $12 target, H.C. Wainwright lifted its target to $12 from $10, and BTIG raised its own target to $12 from $10 while maintaining a Buy rating.
Uniform targets roughly 60% to 70% above the prior close matter for a company of this size. Orchestra BioMed carries a market capitalization of roughly $600 million, so sell-side conviction shifts the perceived risk-reward profile materially. The company also confirmed it would participate in the Piper Sandler 38th Annual Healthcare Conference, keeping management in front of institutional investors.
The re-rating rests on two verifiable operational pillars. First, the BACKBEAT global pivotal trial evaluating AVIM Therapy randomized 349 patients, exceeding its enrollment target, and management plans to submit primary endpoint data for a late-breaking presentation at the Heart Rhythm Society's 2027 meeting. Medtronic's regulatory filing is contingent on positive results.
Second, the company closed an underwritten offering of 15 million shares at $5.00, with the underwriters' option exercised in full, generating approximately $86.3 million in gross proceeds and about $80.5 million net. Combined with roughly $101.9 million in cash and marketable securities at the end of the third quarter, management projects funding through 2028. Offering overhang, which had capped the shares near the $5 issue price, has now been absorbed.
Third-quarter results were mixed but supportive of sentiment. Orchestra BioMed reported a GAAP loss of $0.30 per share, better than the $0.40 consensus loss, while revenue of $91,000 came in below expectations as collaboration revenue winds down. Research and development spending rose 26% to $17.7 million, consistent with a company running two pivotal programs. For a pre-commercial device developer, the trial timeline and balance sheet carry more weight than the top line, and both improved.
Volume has been running well above the roughly 370,000 to 425,000 shares that change hands on an average session. The stock traded 1.57 million shares on Friday's 17.89% surge and another 755,585 shares on Monday, confirming institutional participation rather than a thin-book artifact.
The stock sits comfortably above both its 20-day and 200-day moving averages, and Wednesday's trade pushed it past the previous 52-week high of $7.45. A double-digit gain of this magnitude in a sub-$1 billion medical-device developer is idiosyncratic rather than index-driven; the move reflects company-specific repricing, not a broad healthcare or medtech rally. The 20-day average near $6.20 and rising trendline now serve as the first reference points on any pullback.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. This event scores 44 out of 100.
The verified news is moderate rather than transformative: analyst targets raised to $12, a research and development day, a pivotal trial that exceeded its enrollment target, and a completed financing that extends runway into 2028. None of these is a binary clinical outcome or a confirmed approval. The price move was more unusual than the news, but not extreme by this stock's own standards. Over the past 60 sessions the average absolute daily change has been about 3.1%, and Wednesday's 10.62% gain is roughly 3.4 times that, with only one session in that window — Friday's 17.89% jump — producing a larger move. Moderate fundamental news plus a clearly above-normal but not unprecedented move combine into a mid-range score.
The dominant scheduled event is the BACKBEAT primary endpoint readout, targeted for a late-breaking presentation at HRS 2027 in the second quarter, with AVIM commercialization targeted as early as the first half of 2028. The Virtue Trial is enrolling toward a 740-patient pivotal study, and next-quarter updates on enrollment pace will be watched closely. Fourth-quarter and full-year 2026 financial results are expected in March 2027.
Analyst consensus stands at Strong Buy across seven to eight covering firms, though estimates hinge entirely on trial execution. Key risks include the binary nature of the BACKBEAT readout, continued cash consumption of roughly $17 million per quarter in research and development, dilution risk should timelines slip beyond the 2028 runway, and the possibility that post-offering supply resurfaces on rallies. Investors should also monitor Medtronic's own pacing franchise commentary, since the AVIM economics depend on partner commercialization.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. The bots vary widely by strategy, timeframe, performance metrics, and traded symbols, allowing users to compare approaches side by side. For investors navigating volatile small-cap movers like OBIO, this page offers a structured way to explore systematic strategies that are currently working in live markets. Review the lineup regularly, as featured bots rotate with changing conditions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
OBIO moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend. In 43 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on OBIO as a result. In 73 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for OBIO just turned positive on November 11, 2026. Looking at past instances where OBIO's MACD turned positive, the stock continued to rise in 28 of 48 cases over the following month. The odds of a continued upward trend are 58%.
The 10-day moving average for OBIO crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +20.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where OBIO advanced for three days, in 165 of 216 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
OBIO broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. OBIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.668) is normal, around the industry mean (3.592). P/E Ratio (-6.762) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (11.198) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology